Leaving
You are now leaving Cancer Survivors Network. Click the link to continue to http://www.prnewswire.com/news-releases/fda-accepts-genentechs-biologics-license-application-for-subcutaneous-formulation-of-rituximab-300356307.html.
You are now leaving Cancer Survivors Network. Click the link to continue to http://www.prnewswire.com/news-releases/fda-accepts-genentechs-biologics-license-application-for-subcutaneous-formulation-of-rituximab-300356307.html.